Telehealth clinic Shed announced on Tuesday that it has introduced Low-Dose Naltrexone (LDN), a therapeutic solution for individuals managing chronic pain, autoimmune diseases and metabolic health challenges.

The company said that LDN works by naturally balancing the immune system, reducing inflammation and providing pain relief, offering an alternative for patients seeking to address the root causes of their conditions.

LDN is a medication that temporarily blocks opioid receptors in the body, triggering a rebound effect that stimulates endorphin production. These natural endorphins regulate the immune system, reduce inflammation and provide pain relief. This mechanism makes LDN a promising treatment option for individuals battling autoimmune diseases, chronic pain, gastrointestinal disorders and even mental health challenges.

Morley Baker, Shed founder and CEO, said: "LDN is an exciting addition to our holistic approach to health. With the addition of LDN, we're able to provide a comprehensive solution that not only helps patients manage weight but also supports their overall health by targeting chronic conditions that have long been difficult to treat."